Osteosarcoma is the most common malignant bone tumour affecting children and adolescents.
Importantly, clinical outcomes have not improved for decades, and bone tumours remain a leading cause of cancer-related death in adolescents.
Precision oncology has the potential to advance treatment options, yet its widespread application is hindered by complex methodologies.
Using state-of-the-art technologies to mimic the tumour microenvironment, this study aims to analyse drug responses to determine effective therapeutic options specific to the individual tumour. This will accelerate the translation of precision medicine from bench-to-bedside for childhood sarcoma patients.